China Biologic Products Holdings (China Biologic Products Holdings) Change In Payables And Accrued Expense : $1.4 Mil (TTM As of Sep. 2020)

View and export this data going back to 2001. Start your Free Trial

What is China Biologic Products Holdings Change In Payables And Accrued Expense?

China Biologic Products Holdings's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2020 was $0.5 Mil. It means China Biologic Products Holdings's Accounts Payable & Accrued Expense increased by $0.5 Mil from Jun. 2020 to Sep. 2020 .

China Biologic Products Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2019 was $4.0 Mil. It means China Biologic Products Holdings's Accounts Payable & Accrued Expense increased by $4.0 Mil from Dec. 2018 to Dec. 2019 .

China Biologic Products Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for China Biologic Products Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biologic Products Holdings Change In Payables And Accrued Expense Chart

China Biologic Products Holdings Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

10.16

13.21

23.85

28.26

3.99

China Biologic Products Holdings Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															3.49	-1.85	1.01	1.71	0.50

China Biologic Products Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.4 Mil.

China Biologic Products Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of China Biologic Products Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biologic Products Holdings (China Biologic Products Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Biologic Products Holdings Inc (NAS:CBPO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Chaoyang Park Road, 18th Floor, Jialong International Building, Chaoyang District, Beijing, CHN, 100125

Website

http://www.chinabiologic.com

China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.

Executives

Zhijing Cbpo Liu	officer: Corporate Vice President	19 CHAOYANG PARK ROAD 18/F, JIALONG INTERNATIONAL BUILDING BEIJING F4 100125
Sean Shao	director	21ST FLOOR, EVERBRIGHT BANK BUILDING, ZHUZILIN, FUTIAN DISTRICT, SHENZHEN, GUANGDONG F4 518040
David Gao	director, officer: Chief Executive Officer	C/ BEIJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Albert Yeung	director	C/O BEIJING MED-PHARM CORPORATION 600 WEST GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
David Hui Li	director	C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017
Min Fang	director	UNIT 2206, BUND CENTER OFFICE TOWER NO. 222 YANAN ROAD (EAST) SHANGHAI F4 200002
Zhijun Tong	director	C/O BMP SUNSTONE CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Joseph Chow	director	10110 SORRENTO VALLEY ROAD SUITE C SAN DIEGO CA 92121
Yungang Lu	director	4TH FLOOR, ZHONGDIAN INFORMATION TOWER 6 ZHONGGUANCUN S. ST., HAIDIAN DIST. BEIJING F4 100086
Warburg Pincus Llc	10 percent owner	450 LEXINGTON AVENUE, NEW YORK NY 10017
Wp X Biologics Llc	director, 10 percent owner	C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK X1 10017
Warburg Pincus X Partners, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus Private Equity X, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X Gp L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017